Prescription (Legal) Drug Misuse and Addiction in the United States
A Huge Problem That Demands Our Attention. So We Are Planning an Article Series.
For years, public discussion has centered on illicit drugs and opioid overdose. That focus was necessary — but it left a parallel and structurally underexamined problem largely untouched: dependence and addiction phenotypes emerging from legally prescribed medications, many of them classified as “non-addictive.”
Our goal is to help highlight and make a pathway to end the pain → treatment → addiction loop. You can be a huge part of that.
Across pain care and adjacent symptom management, multiple drug classes generate predictable neuroadaptation. Different receptor systems — GABAergic, monoaminergic, dopaminergic, glutamatergic, endocrine — can all converge on the same endpoint: tolerance, withdrawal, symptom recurrence, and continued use despite harm. The biology differs. The clinical trap often does not.
This is not a rhetorical claim. It is a mechanistic one. And it demands sustained, structured analysis rather than episodic commentary. It demands willpower to change policy. And new clinical options that are not addictive.
Over the coming weeks, Popular Rationalism will publish a focused investigative series that moves from definitions to data gaps to class-specific pharmacology and finally to system reform.
Here are a few of the articles we have planned, each examining a different structural dimension of prescription-related dependence and pain care reform:
Iatrogenic Dependence and Addiction Phenotypes From Non-Opioid Medications Used in Pain Care
This article analyzes how commonly prescribed non-opioid medications can generate predictable tolerance, withdrawal syndromes, and diagnostic mirroring, mapping pharmacologic mechanisms to real-world continuation cycles across sedatives, antidepressants, gabapentinoids, stimulants, corticosteroids, and other agents.
Non-Addictive Pharmacologic and Non-Pharmacologic Options for Chronic Pain Management: Mechanistic Alternatives to Opioid Dependence
This piece shifts from risk to solutions, outlining mechanism-matched pain strategies — topical agents, SNRIs, sodium-channel blockers, CGRP therapies, structured movement, sleep restoration, and other non-reinforcement-driven approaches — with attention to evidence strength and safety constraints.
Policy Recommendations for Clinician Training and Systems Change to Prevent Iatrogenic Addiction Cycles from Non-Opioid Medications in Pain Care
This article translates the pharmacologic findings into operational reforms, detailing structured workflows, taper safeguards, early-intervention triggers, documentation standards, and clinician training models designed to interrupt withdrawal-driven prescribing spirals.
Advancing Non-Addictive, Humanitarian-Centered Pain Management: Policy Recommendations
This broader policy roadmap examines reimbursement structures, coverage gaps, prescriber education mandates, research priorities, and federal levers needed to align incentives with durable, multimodal, non-addictive pain care.
This is not an argument against medication. It is an argument against blind spots.
Producing this level of structured, mechanistic, policy-relevant analysis requires time, primary-source review, and independence from industry influence. Paid subscriptions make that possible. They fund long-form investigation, rigorous synthesis, and reform-oriented writing that does not depend on advertising or sponsorship.
If you believe that legal prescriptions can generate preventable cycles of dependence — and that confronting those cycles requires clarity rather than ideology — your subscription directly enables this work.
We are having an impact via our effort. This one could prevent the next addiction.
I would urge you to not treat ssri and snri as a risk free alternative. I work in the correctly used medication tapering space of psychotropic medication, and can tell you that serious iatrogenic harm (life threatening) can occur from abrupt discontinuation. In many ways, opioids are easier to discontinue than antidepressants, gabapentinoids, and benzodiazepines. (I say this as someone who has seen all of these properly tapered in individuals without addiction, and who is deeply familiar with the topic)
I will be interested in seeing what you put together.
James, You do not care for patients with chronic pain...I do. You have no idea how debilitating it can be and what a mess has been made of the "oh addiction!" mantra. Many studies have shown that 90+% of patients with chronic pain on opioids are DEPENDENT, but not addicted. (I assume I do not need to explain how one differentiates the two states.) Also, 90+% of diabetics on insulin are DEPENDENT but not addicted. Also 90+% of heart patients on beta blockers are DEPENDENT, but not addicted. There is nothing wrong with dependence if one is thereby able to function. But the big bogeyman "opioids" seems to trigger this "well that's not insulin" reaction and away you go.
Of course there is an addictive subgroup (relatively small) that should be screened out. That deserves some focus. Almost all opioid deaths these days are from fentanyl, not prescription opioids. But the "well get physical therapy" nostrum (and that is all it is) does not work for most chronic pain patients -- they have been there and done that. It's like telling diabetics to eat less and we'll cut off your insulin or make you feel like a criminal after enormous monthly grief to get your prescription refilled.
I fervently hope you will not go down this path for the sake of the millions of people who can function with proper pain relief but who cannot without. Many of them have given up and gone from functional members of society to permanent couch potatoes and most on the "oh no, opioids" side of the aisle (which is more-than-strident) seem thrilled.
I can only despair before reading what I am going to read -- but hope springs eternal. You have been inspired in many subjects and I am a very long term subscriber who has also independently funded your other efforts outside this stack -- but I fear the worst.